CSIMarket
 
Quoin Pharmaceuticals Ltd   (NASDAQ: QNRX)
Other Ticker:  
 
 
Price: $0.3000 $0.00 -0.299%
Day's High: $0.3077 Week Perf: -3.54 %
Day's Low: $ 0.29 30 Day Perf: -51.73 %
Volume (M): 692 52 Wk High: $ 6.18
Volume (M$): $ 208 52 Wk Avg: $0.79
Open: $0.31 52 Wk Low: $0.28



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Quoin Pharmaceuticals Ltd
Quoin Pharmaceuticals Ltd is a privately held, research-driven pharmaceutical company that specializes in the development and commercialization of innovative and affordable pharmaceutical products for the global market. The company is committed to creating high-quality and effective products that meet the needs of patients and healthcare professionals.

The company was founded in 2016 and is headquartered in Hyderabad, India. It has a team of experienced professionals who are dedicated to scientific research, clinical development, regulatory affairs, manufacturing, and commercialization. Quoin Pharmaceuticals focuses on developing drugs in a wide range of therapeutic areas, including oncology, pain management, dermatology, and neurology.

One of the main objectives of Quoin Pharmaceuticals is to improve patient outcomes, and the company does this by investing heavily in R&D. It has a state-of-the-art research facility that is equipped with cutting-edge technology and equipment, enabling it to discover new drugs, study their mechanisms of action, and develop effective treatment strategies.

The company has a strong focus on quality and compliance, and it strictly adheres to international standards and regulations. All its products are manufactured in certified facilities that meet the highest quality and safety standards.

Quoin Pharmaceuticals has an extensive global network of partners, including contract manufacturers, research institutions, and distribution companies. This enables the company to leverage its resources to deliver innovative drugs and cutting-edge healthcare solutions to markets around the world.

Quoin Pharmaceuticals has a strong commitment to sustainability and social responsibility. It recognizes the importance of giving back to the community, and it supports a range of initiatives in education, healthcare, and environmental conservation.

Overall, Quoin Pharmaceuticals is a dynamic and innovative pharmaceutical company that is dedicated to improving patient outcomes by developing safe, effective, and affordable drugs.


   Company Address: 42127 Pleasant Forest Court Ashburn 20148 VA
   Company Phone Number: 980-4182   Stock Exchange / Ticker: NASDAQ QNRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX   -0.72%    
CAPR   -5.93%    
ISCO        2.27% 
PRAX   -4.52%    
SBFM   -8.24%    
TFFP   -77.57%    
• View Complete Report
   



Clinical Study

Quoin Pharmaceuticals Pioneers Hope for Rare Genetic Disorders Positive Interim Results in Netherton Syndrome Clini...

Published Sat, Dec 28 2024 5:37 AM UTC

ASHBURN, Va. December 18, 2024 In a groundbreaking development for the treatment of rare genetic diseases, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company, has announced positive interim data from two ongoing clinical studies involving Netherton syndrome (NS), a rare inherited genetic disorder. This announcement comes on the ...

Clinical Study

QRX003 Innovation Targeting Aberrant Protease Activity in Netherton Syndrome for Breakthrough Treatment,

Published Thu, Dec 19 2024 1:00 PM UTC

QRX003: A Promising New Approach in the Management of Netherton Syndrome Quoin Pharmaceuticals Ltd., a company distinguished by its commitment to addressing unmet medical needs in rare and orphan diseases, recently received FDA clearance to commence a new clinical trial to evaluate QRX003, a topical lotion designed for the treatment of Netherton Syndrome (NS). This developme...

Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd Prepares for Strategic Insights Ahead of Q3 2024 Financial Performance

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX): Navigating Fiscal Challenges While Pioneering Treatments for Rare Diseases Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has carved a niche for itself in the competitive landscape of specialty pharmaceuticals, particularly focusing on treatments for rare and orphan diseases. While the company has faced financial challenges in recent months, including a reported loss of $-0.47 per share for the fiscal period closing September 30, 2024, there are signs of progress in its pipeline that could position it favorably for the future. This article provides an in-depth examination of Quoin Pharmaceuticals? recent financial performance, the implications of its clinical advancements, and how these developments may affect its future outlook. Financial OverviewFor the fiscal period ending September 30, 2024, Quoin Pharmaceuticals Ltd. reported a net loss of $-2.350 million, an increase from the $-1.927 million recorded in the same period a year prior. In terms of earnings per share (EPS), the company's losses have narrowed from $-1.95 in the previous year to $-0.47, signaling improvements in certain operational aspects even amid the ongoing deficit. For comparison, during the preceding reporting period, the company had reported a smaller loss of $-0.39 per share.

Clinical Study

Quoin Pharmaceuticals Advances Clinical Trials for QRX003 A Promising Step Forward in the Fight Against Netherton Syn...

Published Tue, Nov 5 2024 1:00 PM UTC

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a noteworthy player in the realm of clinical-stage specialty pharmaceuticals, has made significant strides in its commitment to developing cutting-edge treatments for rare and orphan diseases. As announced from their headquarters in Ashburn, Virginia on November 5, 2024, the company has commenced clinical testing of its lead product...

Shares

Quoin Pharmaceuticals Co-Founders Lead by Example with Insider Share Purchases, Reflecting Confidence and Commitment,

Published Mon, Sep 9 2024 12:30 PM UTC

Quoin Pharmaceuticals Announces Insider Share Purchases, Signaling Leadership Confidence and Commitment to Company
Facts:
- Quoin Pharmaceuticals, a leading pharmaceutical company, recently announced insider share purchases made by its co-founders, the CEO and COO.
- The purchases have been seen as a signal of leadership confidence and commitment to the company s...







Quoin Pharmaceuticals Ltd's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com